Cargando…

Science, ethics and communication remain essential for the success of cell-based therapies

Cell-based therapeutics, such as marrow or peripheral blood stem cell transplantation, are a standard of care for certain malignancies. More recently, a wider variety of cell-based therapeutics including the use of mesenchymal stromal/stem cells, T-cells, and others show great promise in a wider ran...

Descripción completa

Detalles Bibliográficos
Autores principales: Dominici, Massimo, Nichols, Karen M, Levine, Aaron D, Rasko, John EJ, Forte, Miguel, O’Donnell, Lynn, Koh, Mickey BC, Bollard, Catherine M, Weiss, Daniel J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6126268/
https://www.ncbi.nlm.nih.gov/pubmed/30276292
http://dx.doi.org/10.4103/2394-8108.192525
_version_ 1783353307797913600
author Dominici, Massimo
Nichols, Karen M
Levine, Aaron D
Rasko, John EJ
Forte, Miguel
O’Donnell, Lynn
Koh, Mickey BC
Bollard, Catherine M
Weiss, Daniel J
author_facet Dominici, Massimo
Nichols, Karen M
Levine, Aaron D
Rasko, John EJ
Forte, Miguel
O’Donnell, Lynn
Koh, Mickey BC
Bollard, Catherine M
Weiss, Daniel J
author_sort Dominici, Massimo
collection PubMed
description Cell-based therapeutics, such as marrow or peripheral blood stem cell transplantation, are a standard of care for certain malignancies. More recently, a wider variety of cell-based therapeutics including the use of mesenchymal stromal/stem cells, T-cells, and others show great promise in a wider range of diseases. With increased efforts to expand cell-based treatments to several clinical settings, many institutions around the world have developed programs to explore cellular therapy's potential for safe and effective applications. In legitimate investigations, usually conducted through academic centers or biotechnology industry-sponsored efforts, these studies are regulated and peer-reviewed to ensure safety and clear determination of potential efficacy. However, in some cases, the use of cell-based approaches is conducted with insufficient preclinical data, scientific rationale, and/or study plan for the diseases claimed to be treated, with patients being charged for these services without clear evidence of clinical benefit. In this context, patients may not be properly informed regarding the exact treatment they are receiving within a consenting process that may not be completely valid or ethical. Here, the authors emphasize the importance of distinguishing “proven cell-based therapies” from “unproven” and unauthorized cell-based therapies. This publication also addresses the necessity for improved communication between the different stakeholders in the field, patient associations, and advocacy groups in particular, to favor medical innovation and provide legitimate benefits to patients. Considering the progressive growth of cell-based treatments, their increasing therapeutic value and the expectation that society has about these therapies, it is critically important to protect patients and ensure that the risk/benefit ratio is favorable. This paper is a review article. Literature referred to in this paper has been listed in the references section. The datasets supporting the conclusions of this article are available online by searching PubMed. Some original points in this article come from the laboratory practice in our research centers and the authors’ experiences.
format Online
Article
Text
id pubmed-6126268
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-61262682018-10-01 Science, ethics and communication remain essential for the success of cell-based therapies Dominici, Massimo Nichols, Karen M Levine, Aaron D Rasko, John EJ Forte, Miguel O’Donnell, Lynn Koh, Mickey BC Bollard, Catherine M Weiss, Daniel J Brain Circ Review Article Cell-based therapeutics, such as marrow or peripheral blood stem cell transplantation, are a standard of care for certain malignancies. More recently, a wider variety of cell-based therapeutics including the use of mesenchymal stromal/stem cells, T-cells, and others show great promise in a wider range of diseases. With increased efforts to expand cell-based treatments to several clinical settings, many institutions around the world have developed programs to explore cellular therapy's potential for safe and effective applications. In legitimate investigations, usually conducted through academic centers or biotechnology industry-sponsored efforts, these studies are regulated and peer-reviewed to ensure safety and clear determination of potential efficacy. However, in some cases, the use of cell-based approaches is conducted with insufficient preclinical data, scientific rationale, and/or study plan for the diseases claimed to be treated, with patients being charged for these services without clear evidence of clinical benefit. In this context, patients may not be properly informed regarding the exact treatment they are receiving within a consenting process that may not be completely valid or ethical. Here, the authors emphasize the importance of distinguishing “proven cell-based therapies” from “unproven” and unauthorized cell-based therapies. This publication also addresses the necessity for improved communication between the different stakeholders in the field, patient associations, and advocacy groups in particular, to favor medical innovation and provide legitimate benefits to patients. Considering the progressive growth of cell-based treatments, their increasing therapeutic value and the expectation that society has about these therapies, it is critically important to protect patients and ensure that the risk/benefit ratio is favorable. This paper is a review article. Literature referred to in this paper has been listed in the references section. The datasets supporting the conclusions of this article are available online by searching PubMed. Some original points in this article come from the laboratory practice in our research centers and the authors’ experiences. Medknow Publications & Media Pvt Ltd 2016 2016-10-18 /pmc/articles/PMC6126268/ /pubmed/30276292 http://dx.doi.org/10.4103/2394-8108.192525 Text en Copyright: © 2016 Brain Circulation http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.
spellingShingle Review Article
Dominici, Massimo
Nichols, Karen M
Levine, Aaron D
Rasko, John EJ
Forte, Miguel
O’Donnell, Lynn
Koh, Mickey BC
Bollard, Catherine M
Weiss, Daniel J
Science, ethics and communication remain essential for the success of cell-based therapies
title Science, ethics and communication remain essential for the success of cell-based therapies
title_full Science, ethics and communication remain essential for the success of cell-based therapies
title_fullStr Science, ethics and communication remain essential for the success of cell-based therapies
title_full_unstemmed Science, ethics and communication remain essential for the success of cell-based therapies
title_short Science, ethics and communication remain essential for the success of cell-based therapies
title_sort science, ethics and communication remain essential for the success of cell-based therapies
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6126268/
https://www.ncbi.nlm.nih.gov/pubmed/30276292
http://dx.doi.org/10.4103/2394-8108.192525
work_keys_str_mv AT dominicimassimo scienceethicsandcommunicationremainessentialforthesuccessofcellbasedtherapies
AT nicholskarenm scienceethicsandcommunicationremainessentialforthesuccessofcellbasedtherapies
AT levineaarond scienceethicsandcommunicationremainessentialforthesuccessofcellbasedtherapies
AT raskojohnej scienceethicsandcommunicationremainessentialforthesuccessofcellbasedtherapies
AT fortemiguel scienceethicsandcommunicationremainessentialforthesuccessofcellbasedtherapies
AT odonnelllynn scienceethicsandcommunicationremainessentialforthesuccessofcellbasedtherapies
AT kohmickeybc scienceethicsandcommunicationremainessentialforthesuccessofcellbasedtherapies
AT bollardcatherinem scienceethicsandcommunicationremainessentialforthesuccessofcellbasedtherapies
AT weissdanielj scienceethicsandcommunicationremainessentialforthesuccessofcellbasedtherapies